Zepbound (Tirzepatide) Diarrhea That Won't Go Away: Causes, Red Flags, and What to Do

How common is diarrhea on Zepbound?

In the Zepbound prescribing information's pooled weight-reduction trials, diarrhea was reported in 19% of patients on 5 mg, 21% on 10 mg, and 23% on 15 mg, compared with 8% on placebo [1]. The same trials counted any gastrointestinal adverse reaction in 56% of patients on every Zepbound dose, versus 30% on placebo [1]. The label also says adverse reaction rates from different trials cannot be directly compared, so these figures are the Zepbound trial figures rather than a cross-drug ranking [1].

Some patients stopped Zepbound because of gastrointestinal reactions: 1.9% on 5 mg, 3.3% on 10 mg, and 4.3% on 15 mg, versus 0.5% on placebo. Discontinuation for any adverse reaction was 4.8%, 6.3%, and 6.7%, versus 3.4% on placebo [1].

When it usually eases

The trial pattern was dose-related, rising from 19% at 5 mg to 23% at 15 mg, and the label states that most nausea, vomiting, and diarrhea events occurred during dose escalation and decreased over time [1]. The recommended schedule starts at 2.5 mg once weekly for 4 weeks, then 5 mg, with further 2.5 mg steps after at least 4 weeks on the current dose; 2.5 mg is for initiation and is not approved as a maintenance dose [1].

The sections below cover what the label flags if diarrhea continues.

What to watch for if diarrhea continues

The label's warnings that bear on ongoing diarrhea concern fluid loss and abdominal pain.

Fluid loss. The label's kidney warning describes acute kidney injury, in some cases requiring hemodialysis, reported after marketing, mostly in patients who had gastrointestinal reactions causing dehydration such as nausea, vomiting, or diarrhea [1]. It tells clinicians to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during dose initiation and escalation [1]. The label also reports hypotension in 1.6% of Zepbound-treated patients versus 0.1% on placebo, and more often in patients also taking antihypertensive medicines (2.2% versus 1.2%) [1].

Abdominal pain. The label describes the pain of acute pancreatitis as persistent or severe, sometimes radiating to the back, and it may or may not come with nausea or vomiting [1]. If pancreatitis is suspected, the label directs that Zepbound be discontinued and appropriate management started [1].

Other label warnings that can start as GI symptoms.

• Acute gallbladder disease: cholecystitis was reported in 0.7% of Zepbound-treated patients versus 0.2% on placebo, and cholelithiasis in 1.1% versus 1%. If cholecystitis is suspected, the label calls for gallbladder studies and clinical follow-up [1].
• Severe gastrointestinal reactions: 1.7% on 5 mg, 2.5% on 10 mg, and 3.1% on 15 mg, versus 1% on placebo. Zepbound is not recommended in people with severe gastroparesis [1].
• Serious hypersensitivity: anaphylaxis and angioedema have been reported with tirzepatide, and the label says to seek medical attention promptly and discontinue Zepbound if such a reaction is suspected [1].

What the label says when a dose is not working out

The Zepbound label calls for kidney-function monitoring when reactions could cause fluid loss, and it says that if a maintenance dose is not tolerated, a lower maintenance dose may be considered [1]. It frames the choice of maintenance dose as a balance of treatment response and tolerability [1].

The approved maintenance doses are 5, 10, or 15 mg weekly for weight reduction, and 10 or 15 mg weekly for obstructive sleep apnea [1]. The label's drug interactions section names insulin and sulfonylureas, oral medicines in general (warfarin as an example) and oral hormonal contraceptives; it does not name loperamide or any other antidiarrheal [1].

What to keep track of

Useful details to record are how often stools are loose and what they look like, and whether pain is persistent or radiating to the back. The 7-point Bristol stool form scale is one way to record stool form: in a study of 66 volunteers, stool form scores tracked measured whole-gut transit time [2]. Fluid intake belongs in the same record, given the label's emphasis on volume depletion [1].